Printer Friendly

ALPHA THERAPEUTIC CORP. FILES FOR ARBITRATION IN UNIVAX AGREEMENT

 LOS ANGELES, Feb. 4 /PRNewswire/ -- Alpha Therapeutic Corporation announced today that on Jan. 7, 1993, it filed for arbitration pursuant to its license and distribution agreement with Univax Biologics, Inc. (NASDAQ-NMS: UNVX).
 Alpha is asking for a return of all monies paid by Alpha to Univax in the amount of $2,914,000 and for an award of other damages, attorneys' fees, and costs that are associated with Univax's negligent or intentional misrepresentation.
 Under arbitration provisions of the 1990 agreement between Alpha and Univax regarding the development of a human polyclonal antibody product for use of prevention and treatment of adult sepsis, Alpha alleges that Univax has failed to complete any milestone required under the agreement, that Univax misrepresented the status of its lipid A vaccine at the time the agreement was entered into, that Univax misrepresented its ability to conduct preclinical and clinical trials, and that Univax misrepresented the cost of the project necessary to obtain a product license by increasing said costs from a $3,000,000 project to a $60,000,000 project.
 Alpha Therapeutic Corporation is one of the world leaders in the collection, production and distribution of life-saving blood plasma products.
 -0- 2/4/93
 /CONTACT: Edward A. Colton, Esq., of Alpha, 213-227-7605/
 (UNVX)


CO: Alpha Therapeutic Corporation; Univax Biologics, Inc. ST: California IN: MTC SU:

GK-LR -- NY107 -- 3129 02/04/93 15:35 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1993
Words:230
Previous Article:WABC-TV IS THE TOP-RATED STATION IN NEW YORK IN THE JANUARY 1993 RATINGS RACE
Next Article:NATIONAL SAFETY COUNCIL STARTS INTERNATIONAL OPERATION, WILL OPEN REGIONAL OFFICE IN BRUSSELS
Topics:


Related Articles
CEL-SCI CORPORATION TO FILE ARBITRATION PROCEEDINGS AGAINST ALPHA 1 BIOMEDICALS, INC.
NORTH AMERICAN BIOLOGICALS, INC. AND UNIVAX BIOLOGICS, INC. MERGER CLEARS FTC REVIEW
Pharming and Genzyme Transgenics End Arbitration and Amend Cross-License Agreement
Genzyme Transgenics, Interferon Sciences to Collaborate on Development of Transgenic Interferon Alpha
Genzyme General and Pharming Form Joint Venture to Develop Treatment for Pompe's Disease.
Genzyme General Obtains Rights to Pompe Disease Therapy from Synpac.
Genzyme Files Suit Against Transkaryotic Therapies for Patent Infringement.
Important US Patent Secures Pharming's Position on human alpha-Glucosidase.
Neurochem announces award denying majority of Immtech's claims.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters